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a b s t r a c t
microRNAs (miRNAs) have a pivotal role during the formation and function of the cardiovascular
system. More than 300 miRNAs have been currently found within the mammalian genome,
however only few specific miRNAs, named endomiRNAs, showed conseved endothelial cell
expression and function. In this review we present an overview of the currently known
endomiRNAs, focusing on their genome localization, processing and target gene repression
during vasculogenesis and angiogenesis.
& 2012 Published by Elsevier Inc.
miRNAs biogenesis and regulation
microRNAs (miRNAs) are highly conserved small non-coding
RNAs (!22 nucleotide—nt) that play an important role in the
regulation of gene expression at the post-transcriptional level.
miRNAs are located within introns and exons of protein coding
genes or in intergenic regions. They are transcribed by RNA
polymerase II as long primary miRNA transcripts (pri-miRNA)
containing one or several hairpin structures with 50CAP and
polyadenylated tails [1]. In the nucleus, the pri-miRNA is cleaved
by a microprocessor complex, the RNAse III enzymes Drosha and
DGR8 [2]. This cleavage step results in an !65 nt precursor
miRNA (pre-miRNA) which is exported to the cytoplasm in
association with Exportin-5 and cleaved by Dicer to 18–24 nt
duplex. Finally, this miRNA duplex is loaded into the RNA-
induced silencing complex (RISC) together with the Argonaute
(Ago) proteins. RISC can bind to the 30-untranslated region (UTR)
of the target mRNA on a partial miRNA–mRNA complementarity
to the first 8 nt within the 50 miRNA end called the seed sequence
[3]. This binding causes the degradation of the target mRNA and
consequent translational inhibition [4]. miRNAs derived from
intronic hairpins are called mirtrons and they bypass the
cleavage step from Drosha while nuclear transport and cleavage
are common to the canonical miRNA biogenesis pathway. The
processing of the miRNAs is a tightly regulated mechanism
involving regulatory proteins, editing of miRNA transcripts and
leading to either elevated or decreased miRNA levels (Fig. 1) [3].
These regulatory proteins can be subdivided into three groups:
Drosha binding/associated proteins, Dicer binding proteins and
proteins that bind to the terminal loop of the pri- and/or pre-
miRNAs. For example, the DEAD box helicase p68/p72 complex
facilitates the processing of a set of miRNAs by binding Drosha
[5]. This complex can be activated upon interaction with Smad
factors after Transforming Growth Factor b (TGF-b) and Bone
Morphogenesis Protein (BMP) stimulus [6]. Similarly, TAR RNA
binding protein (TRBP) can interact and stabilize Dicer after
phosphorylation mediated by the mitogen-activated protein
kinase (MAPK) signaling pathway [7,8]. Therefore, alteration
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of miRNA processing by ERK may result in a pro-growth factor
phenotype. Finally, many other RNA binding proteins such as
LIN28 [8], hnRNP [9] and KSRP [10] can directly bind to the
terminal loop of different pre-miRNAs and modulate the cleavage
of their mature sequence in different cell types or different stages
of developments. The most recent mechanism discovered on
miRNA editing and destabilization is the conversion of adenosine
to inosine within the pri- or pre-miRNA by the adenosine
deaminase ADAR [11]. Splice variants of ADAR have been
identified in the cardiac tissue suggesting a specific ADAR/
miRNAs regulation in different cellular contexts. However, the
expression and function of this protein in the cardiovascular
system remain uninvestigated.
Targeting miRNAs
To probe the in vitro and in vivo function of miRNAs many
approaches have been developed to block the miRNAs activity.
Currently, three strategies are used in miRNA loss-of function
studies: genetic knockouts, miRNAs sponge, and antisense oligo-
nucleotides. miRNA knockout allows the generation of animal
systems with the whole mount or tissue specific deletion of
candidate miRNA genes. The generation of knockouts i Q2n Caenor-
habditis elegans and Drosophila as well in mouse model has been
extensively used to unravel the function of miRNAs in early
embryonic development [12]. Recently, a genome-wide knockout
resource covering 476 mouse miRNA genes was described and
embryonic stem cells repertories have been made available to
improve the studies of the miRNAs in vivo [13]. So far, the
majority of the !25 miRNAs mouse knockouts do not exhibit
severe defects during embryonic development. Indeed, many
miRNA families exist as duplicates or have identical seed regions,
thus there remains the question of functional redundancy. In
addition, genome deletion of a single miRNA encoded within a
gene cluster is particularly difficult without affecting the expres-
sion of the other miRNAs. Alternative methods to perform gene
knockout may overcome family complexity and redundancy of
miRNA gene function. Recently improvements in artificial tran-
scription activator-like effector nucleases (TALENs) provide a
promising and powerful new approach for precise genome
targeting of miRNAs genes [14].
miRNA sponges are transcripts with repeated miRNA antisense
sequences that can sequester miRNAs from endogenous mRNA
targets. Specific design of sponges can bind and sequester all
miRNAs seed family members or a single miRNA within a cluster
offering additional advantages in the analysis of complex miR-
NAs activity. Sponge has been proven to induce transient, long
term and tissue specific miRNAs inhibition in several animal
models [15]; however, the success of their activity is strongly
dependent on the endogenous miRNA expression levels. Chemi-
cally modified antisense nucleotides are the most common
approach to perform loss of miRNA function studies. A variety
of commercial chemical modifications such as the 20-O-Methil
(20-O-ME), 20-O-methoxyethyl (20-MOE) or locked nucleic acid
(LNA) and morpholino oligonucleotides are now available. These
modifications confer nuclease resistance and high binding affi-
nity to target miRNAs [16]. These oligos named antimiR can
target miRNAs at different stages of their biogenesis or block
miRNAs activity by binding the mature miRNA sequence or by
targeting the miRNA binding site within the target mRNA [17].
Several studies evaluated the efficiency of different modified
antimiR mediated inhibitions in both vitro and in vivo [16]. This
strategy has been used to block the activity of individual miRNAs
while new strategies still have to be developed to block miRNA
families. A recent publication has shown the efficiency of eight
nucleotides LNA modified phophotiorate nucleotide, named tiny
LNA, complementary to the seed region of the target miRNAs.
Tiny LNA inhibits individual miRNA and/or miRNA families in
culture cells and several tissues when delivered to the adult
mouse [18]. AntimiR or tiny LNA oligonucleotides’ disadvantages
are related to their transitory and partial inhibitory effect in
addition to potential off-target effects.
Target prediction tools
Open-access bioinformatic databases have been developed to
facilitate the analysis of miRNAs and their target prediction [19].
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Fig. 1 – miRNAs processingQ3 and regulation. miRNA precursors
(pri-miRNA) are processed by Drosha and DGCR8 proteins into
smaller RNA hairpins named pre-miRNAs. Protein–protein or
RNA binding proteins are able to inhibit (red) or promote
(green) pri-in to pre-miRNA processing with the nucleus.
After export to the cytoplasm, pre-miRNAs are associated with
the endonuclease DICER and other regulatory protein such as
TRBP. DICER cleaves the pre-miRNAs into a !22 nt duplex
miRNA which is incorporated in the RNA-inducing-silencing-
complex (RISC) where the mature miRNA associates with
AGO2 to induce translation repression of the target mRNA.
This process can be regulated by several growth factor
singling pathways through ERK-MAP kinase or SMAD
activation. hnRNP¼heterogeneous nuclear riboprotein;
KSRP¼KH-type splicing regulatory protein; SMAD¼mothers
against decapentaplegic homolog; ADAR¼adenosine
deamenases acting in RNA. (For interpretation of the
references to color in this figure, the reader is referred to the
web version of this article.)
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Prediction of miRNA–mRNA interactions is a challenging task,
due to the short length of miRNAs, the requirement of only
partial homology for binding, the redundancy among members of
an miRNA family, and the existence of multiple putative miRNA
recognition sites [20].The majority of the computational target
prediction programs are based on several features, such as
complementarity between the 50-seed of the miRNA and the
30-UTR of the target mRNA, thermodynamic stability of the
miRNA–mRNA duplex, conservation among species, and the
presence of several miRNA target sites. Several different in silico
target prediction programs exist to identify miRNA-target pre-
diction. Such prediction programs must be used carefully since
(i) the genome is not fully sequenced, (ii) only a limited number
of miRNA targets have been experimentally validated, and
(iii) there is low conservation among species regarding mature
microRNAs sequence as well as the target prediction. Experi-
mental high-throughput studies (such as chromatin marks and
poly(A)-site mapping followed by RNA-Seq) are needed to allow
for generation of precise prediction algorithms [21,22].
miRNA-target validation tools
Efficient experimental strategies are needed to validate computa-
tionally predicted miRNA target genes. To validate predicted
miRNA–mRNA interactions, several experimental approaches have
been used, such as biochemical methods (luciferase assays, qRT-
PCR, western blotting, and RNA seq), ‘‘omics’’ approaches (SILAC,
LAMP), and RISCome analysis (quantification of mRNAs in the RNA-
induced sequencing complex; RISC RNA sequencing, RIP-chip) [23].
Experiments performed in cultured cell lines are usually useful to
validate microRNA effects on target mRNA. Recently, animal models
have also been used to validate target mRNA in vivo. Novel
techniques have been implemented in the zebrafish model such
as fluorescent miRNA sensor and morpholino (MO) target protector.
In the first case, validation of the target prediction is tested using a
reporter assay based on monitoring GFP/mCherry fluorescence in
zebrafish embryos microinjected with mRNA encoding the fluor-
escent reporter fused to the 30-UTR of the target gene, in the
presence or absence of specific miRNA duplex. In this assay, a
decrease in fluorescence in the presence of miRNA duplex indicates
miRNA-mediated repression and then the confirmation of the
target in vivo. In the second case, MOs are designed to be
complementary to specific miRNA-binding sites in target mRNAs.
In this way MOs have been shown to efficiently protect the target
mRNA from translational inhibition or degradation. To study the
regulation of a particular target, it is important to establish first that
the 30-UTR is regulated by a particular miRNA. miRNAs may speed-
up degradation or slow-down translation of their targets, but
repression caused by either mechanisms can be assessed by
measuring protein output of a reporter. The efficiency of ‘‘target
protectors’’ to block the interaction of miRNAs with a particular
binding site in a target mRNA can also be investigated by co-
injections with reporter mRNAs containing a GFP/mCherry coding
sequence and a 30-UTR region with the miRNA-binding site.
Subsequently, a tested target protector can be used to study
whether protection of a specific target mRNA from silencing has
any biological effect in a tissue-specific manner (by generation of a
cell autonomous miRNA sensor). Recently, a proteomics approach
to validate predicted miRNA targets in C. elegans by using
quantitative targeted proteomics via selected reaction monitoring
(RIP-chip-SRM) has been reported [21]. This technique can be
applied to validate candidate lists generated by computational
methods or in large-scale experiments, and the described strategy
should be readily adaptable to other organisms.
miRNAs function in endothelial cells: the
‘‘endomiRNAs’’
The mammalian genome encodes !300 highly conserved miRNAs
(!1–2% of the genes) able to regulate, at least by bioinformatics
prediction, over 60% of protein coding genes [24]. In the past five
years this magnitude of gene regulation by miRNAs, has been
revised based upon numerous evidences : (1) in animal system
miRNAs are usually expressed in a non-correlated manner with
their predicted mRNA targets [25]; (2) majority of the miRNAs
produce subtle proteins reduction (o2 fold change) [26]; (3) many
miRNAs can be deleted in vivo without causing evident phenotypes
[27]. If so, what is the real inhibitory potential of miRNAs?
Increasing evidence suggested that miRNAs confer robustness to
complex signaling pathways, functioning as ‘‘buffers’’ to gene
fluctuations. They can reinforce transcriptional programs and
attenuate aberrant transcripts thereby conferring accuracy and
uniformity to developmental transitions, cell fate switches and
stress-responses [28]. The remodeling of the vascular system is a
sophisticated result of the balance between stimulators and inhi-
bitors pathway. These pathways are fed by a web of vascular
growth factors and downstream proteins signaling tightly con-
trolled by feedback loops and redundant components. For these
properties the cardiovascular system is particularly sensitive to the
regulation of miRNAs. In vitro and in vivo studies have shown that
Dicer has an important function in angiogenesis. Dicer mutant mice
embryos and yolk sack manifest angiogenic defects [29]. Accord-
ingly, mice carrying an endothelial tissue specific deletion of Dicer
shows defects in postnatal angiogenic response to a variety of
stimuli, including exogenous VEGF, tumors, limb ischemia and
wound healing [30]. Finally, genetic silencing of Drosha expression
in endothelial cells also results in a reduction in capillary sprouting
and tube formation [31]. In this review, we will summarize the
state-of-art on the major conserved families of miRNAs expressed
in endothelial cells, endomiRNAs miR-126 and themiR-17-92,
miR-23-27-24 and miR-222-221clusters (Fig. 2).
miR-126
In 2008, three independent groups analyzed and reported defects
in miR-126 deficient vascular cells, varying from zebrafish to
human and mice [32,33]. miR-126 is the most important and
possibly the only endothelial-specific miRNA in vertebrates. It is
expressed in the vascular tree of vertebrate throughout devel-
opment. In addition, miR-126 has been found as one of the most
enriched microRNAs in cultured human endothelial cells and in
endothelial cells derived from embryonic stem cells or isolated
from mouse embryos. miR-126 has been clearly shown to be a
master miRNA in vascular function working as a key positive
regulator of angiogenic signaling in vitro and in vivo [32]. miR-
126 is encoded in an intron of EGF-like domain 7 (Egfl7) gene.
Egfl7 encodes a secreted matrix component that is produced by
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angiogenic stimuli and induces endothelial migration [34]. Since
miR-126 is located within an intron of the Egfl7 gene, questions
arise whether the vascular abnormalities seen in miR-126 studies
are due to the loss of miR-126 or Egfl7 activity. Comparison
between miR-126 and Egfl7 knock out models indicates that the
severe vascular defects are only observable in animal deficient in
miR-126, highlighting the requirement of miR-126 for the
developing and postnatal vasculature. Remarkably, deletion of
miR-126 in mice results in vascular developmental defects such
as delayed angiogenic sprouting, widespread hemorrhaging, and
partial embryonic lethality [33]. In addition, miR-126 mutant
mice that successfully complete embryogenesis display dimin-
ished angiogenesis and increased mortality after coronary liga-
tion, a model for myocardial infarction. Also endothelial cells
deficient in miR-126 fail to respond to angiogenic factors,
including VEGF, epidermal growth factor (EGF), and bFGF. In
zebrafish, knockdown of miR-126 by MO injections induced
collapsed blood vessels and cranial hemorrhages in the develop-
ing organism suggesting its primary role for maintaining vascular
structure during development [32]. Mechanistically, two direct
targets of miR-126 that seem to explain these angiogenic defects
are Sprouty-related EVH1 domain-containing protein 1 (Spred1)
and a regulatory subunit of PI3K, PIK3R2 (also known as p85b)
[33]. Because Spred1 and PIK3R2 are negative regulators of
cellular signaling cascades, affecting the MAPK and PI3K signal-
ing pathways, respectively, miR-126 promotes VEGF and other
growth factors signaling by targeting multiple signaling pathways,
miR-126 may fine-tune angiogenic responses. Spred1, which is a
negative regulator of cell survival, was validated as a direct miR-
126 target being expressed in miR-126 deficient zebrafish. Indeed,
downregulation of miR-126 in endothelial progenitor cells from
diabetes human patients impairs their functional properties, via
target gene Spred-1 [35]. Recently, VEGF-A has been proposed as
another important target of miR-126 [36]. More recent studies on
zebrafish embryos suggested that miR-126 expression is under
control of the mechano-sensitive zinc finger transcription factor
klf2a. In this model, pulsatile flow induces expression of miR-126
within the endothelia cells to modulate VEGF signaling during the
remodeling of the aortic arches [37]. Many endothelial miRNAs can
also be involved in vascular inflammation particularly in leukocyte
activation and their infiltration into the vascular wall. miR-126 is a
good example. Indeed, a recent study provides first evidence that
miRNAs control vascular inflammation since miR-126 inhibits the
expression of vascular cell adhesion molecule 1 (VCAM-1), which
mediates leukocyte adherence to endothelial cells. Thus, decreasing
miR-126 in endothelial cells it is possible to increase TNFa-
stimulated VCAM-1 expression and enhances leukocyte adherence
to endothelial cells. Using the embryonic stem differentiation
system to model primitive erythropoiesis and miR-126 null
embryos, it has been found that miR-126 regulates the termination
of EryP-CFC development in vivo by targeting VCAM-1 [38].
miR-17-92 cluster
ThemiR-17-92 cluster is a polycistronic miRNA gene and encodes for
six mature miRNAs namely miR-17, miR-18a, miR-19a, miR-20a,
miR-19b and miR-92a. All the members of this cluster are highly
expressed in endothelial cells regulating vascular integrity and
angiogenesis [39]. Interestingly recent evidence showed that mem-
bers of the miR-17-92 family are differentially expressed during
endothelial cells differentiation of pluripotent stem cells. While miR-
17, miR18a and miR-19a were increased upon induction of endothe-
lial differentiation, miR-92a was decreased. Even so, the inhibition of
each of these miRNAs did not affect endothelial cell differentiation
similarly to miR-126 activity which is required for endothelial cell
function but not for endothelial differentiation [40]. Numerous
studies focus on the endothelial cell function of miR-17-92 cluster
that revealed complex and controversial results. The entire cluster is
highly up-regulated in multiple human tumor cell types, however
only miR-18a and miR-19a have a pro-angiogenic function during
tumor angiogenesis. The overexpression of these miRNAs in tumor
cell, repressed the secreted anti-angiogenic factors thrombospondin
(TSP-1) and connective tissue growth factor (CTGF), inducing an
increase of neovascularization in a paracrine fashion [41]. Interest-
ingly, these miRNAs showed an anti-angiogenic function when over
expressed directly in endothelial cells. miR-17a, miR18a, miR19a and
miR-20b inhibited endothelial cells sprouting when ectopically
expressed, while individual miRNA knockdown promotes angiogen-
esis. In these experiments the protein kinase Jak1 was identified as
the major target mRNA responsible for the pro-angiogenic effect
[25]. Accordingly, the over expression of another member of the
cluster, miR-92a inhibits vascular network formation in matrigel
assay via targeting integrin a 5 (ITGA5) and indirectly suppressing
eNOS production [42]. The anti- or pro-angiogenic function of the
miR-17-92 cluster seems strictly related to the cellular context.
Interesting, the miR-17-92 members are also differentially regulated
in endothelial cells exposed to hemodynamic force [43]. miR-92a is
downregulated in endothelial cells exposed to laminar flow while its
mature sequence is upregulated by oscillatory flow consistently with
its atheroprotective function in vivo [43]. The differential expression
and therefore function of the single miRNAs derived frommiR-17-92
cluster are mostly due to post-transcriptional regulation of the pri-
miRNA [44]. Consequently, physiological and pathological conditions
as well as tissue dependent miRNA editing events can modulate the
expression of a single miRNA belonging to the miR-17-92 cluster.
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Fig. 2 – Schematic representation of the endomiRNAs and
their targets. Four different microRNAs families have been
implicated in controlling endothelial cell behavior and
signaling. Endothelial microRNAs–endomiRNAs-include miR-
126 and miR-23-27-24, miR-17-92 and miR-222-221 clusters.
These families of microRNAs have been found to be expressed
in endothelial cells (or cells that interact with the
endothelium) and thus regulate endothelial cell responses.
See text for detailed information.
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Further investigations need to be performed to elucidate this aspect.
Mouse targeted deletion of the miR-17-92 cluster reveals essential
functions of these miRNAs during embryonic development. The
functional analysis of the miR-17-92 cluster is complicated by the
existence of two paralog clusters miR-106a-363 and miR-106b-25
generated by duplication event during evolution [45]. Mice lacking
miR-17-92 or both miR-17-92 and miR106b-25, died shortly after
birth showing lung hypoplasia and impaired B cell development due
to an increased level of the pro-apoptotic Bim protein [45]. The
characterization of the vascular development in these mice is
currently missing. In addition, the endothelial specific deletion of
miR-17-92 cluster will be necessary to elucidate the function of
miR17-92 cluster during the embryonic vascular morphogenesis.
miR-23-27-24 cluster
The miR-23/27/24 cluster exists in the mammalian genome as
duplicate gene located in different genomic locations: miR-23b,
miR-27b and miR-24-1 are located within the intron region at
the human chromosome 9q22.32 while the intergenic cluster
miR-23a, miR-27a and miR-24-2 gene are localized at the
chromosome 19q13.13. The mature sequence of the respective
miR-23a/b, 27a/b and miR-24 1 and 2 are identical and highly
conserved among vertebrates. The dissection of miR-23-27-24
gene expression and function is intrinsically complicated by their
genome structure. For example, miR-24 pri-miRNA and the
mature sequence is up-regulated after BMP2 stimulation in
mesenchymal cells, while miR-27b and 23b are unaffected by
this treatment suggesting that even if they are in close proximity
within the genome the pri-miRNA of miR-24 and miR-23-27 are
transcribed independently [45]. All the members of this cluster
are highly enriched in vascularized organs and endothelial cells.
Silencing of miR-23-27 inhibits the angiogenesis in response to
VEGF by impairing the activation of MAP and PI3K-AKT kinase
signaling pathway. Similarly, silencing of miR-23-27 suppresses
choroid revascularization after laser injury [46,47]. miR-23 and
miR-27 sequences possess different seed regions, therefore they
can target diverse mRNA targets. However, in endothelia cells
both miR-23-27 bind the Sprouty2 and sema6A 30-UTR reinfor-
cing the reciprocal inhibitory activity. The repressions of these
two target genes by miR-23-27 serve to maintain an active RAC/
RAF/ERK pathway after VEGF stimulation [46,47]. Intriguing,
miR-24 expression is highly induced in endothelial cells after
stress condition such as oxidative stress. Indeed, miR-24 acti-
vates pro-apoptotic signaling within the vasculature of the
myocardium after myocardial infarction and in vivo treatment
with antimiR against miR-24 improves vascularization and pre-
serves cardiac function after myocardial infarction. GATA2 and
p21 activated kinase Pak1 seem to be the major gene targets
assigned to the miR-24/pro-apoptotic function during vascular
remodeling [48]. Currently there are no mouse knockout models
for the miR-23-27-24 cluster and therefore no data that can
suggest their function during embryonic vascular development.
However, the downregulation of miR-27 in zebrafish embryos
induced venous remodeling and angiogenesis of intersegmental
vessel (ISV) defects. The miR-27 loss of function phenotype can
be rescued by the repression of either Sprouty2 or Dll4 genes
proposing these two genes as major miR-27 targets during
zebrafish vascular development [49].
miR-222-221 cluster
miR-222 and 221 are highly conserved miRNAs transcribed from
a common polyadenylated pri-miRNA located on the human
chromosome X. Both miR-221 and miR-222 have a pro-
proliferative effect on cancer cells [50]. miR-222 and miR-221
are also highly expressed in endothelial cells after growth factor
stimulation or in the quiescent state [26]. While both miRNAs
share the same seed region, numerous studies identified different
target genes controlled by miR-221 and miR-222. For example,
compared with miR-222, miR-221 is not biologically relevant for
inflammation mediated by vascular growth factors [51] where
during zebrafish embryonic development miR-222 is dispensable
for vascular remodeling [52]. Similar observations were reported
in a model of liver tumorigenesis, in which miR-221, but not
miR-222 was able to accelerate tumor growth in mice [53]. The
regulatory activities of this miRNA cluster seem to be cell type
dependent. The inhibition of miR-222-221 decreases neointimal
lesion formation but increases re-endotheliazation during hyper-
plasia following vascular injury. Indeed, miR-222-221 are both
highly expressed in endothelial and vascular small muscle cells
(VSMC). In VSMS this cluster have a pro-proliferative and pro-
migratory effect by targeting two cell cycle dependent inhibitors
p27 (cdkn1b/Kip1) and p57 (kip2) [54]. In contrast exogenous
miR-222-221 show anti-proliferative activity in human venous
and lymphatic endothelial cells by targeting numerous target
mRNAs depending on the experimental setting. These targets
include ETS1 transcription factor [55], the stem cells factor
receptor cKit [56] and the transcriptional repressor ZEB2 [57].
However, the molecular mechanism responsible for miR-222-
221 mediated opposite cellular effects is currently unclear.
Importantly, miR-221 expression varies significantly in response
to both serum and VEGF treatment [25] generating discrepancies
between different experimental conditions. The function of the
miR-222-221 cluster during the mouse embryonic development
has not been investigated yet. Recent studies using the zebrafish
model showed that miR-221 is a NOTCH dependent miRNA
required for endothelial tip cells proliferation and migration.
miR-221 promotes endothelial cells sprouting by targeting two
distinct target genes, PIK3R1and p27. miR-221/p27 target reg-
ulation is required to coordinate proliferation, while tuning PI3K
output by miR-221/PIK3R1 repression is fundamental for tip cell
migration upon VEGFC-Flt4 activation [52].
Conclusion
This review summarizes current research progress and knowl-
edge on the roles of miRNAs in regulating endothelial cell
function and signaling. The discovery of miRNAs as regulators
of vascular specific signaling pathways has created new options
for the design of therapeutic agents that could modify gene
expression in vascular-associated disease. Recently, it was dis-
covered that extracellular miRNAs circulate in the bloodstream
and that such circulating miRNAs are remarkably stable [58].
This has raised the possibility that miRNAs may be probed in the
circulation and can serve as novel diagnostic markers for
vascular-related diseases such as myocardial infarction, heart
failure, atherosclerosis, hypertension, and type 2 diabetes. These
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discoveries are expected to present opportunities for clinical
diagnostic and therapeutic approaches in miRNA-based vascular
diseases.
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